Industry landscapes
The companies, capital and talent shaping life sciences in South Korea. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
8 of 1,331 tracked companies have open roles.
220 of 1,331 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 209 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 52.6% of disclosed capital, while 83.5% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $62.95M | 106 | 10 |
| 2017 | $58.06M | 86 | 13 |
| 2018 | $523.64M | 108 | 16 |
| 2019 | $364.29M | 130 | 22 |
| 2020 | $271.72M | 108 | 20 |
| 2021 | $464.43M | 81 | 28 |
| 2022 | $395.21M | 37 | 29 |
| 2023 | $95.73M | 11 | 10 |
| 2024 | $113.26M | 11 | 18 |
| 2025 | $312.61M | 1 | 16 |
Share of all disclosed company funding.
302 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by GVA and Industrial Bank of Korea and others.
Backed by KB Investment and UTC Investment and others.
Backed by Mirae Asset and Daishin Securities and others.
Backed by Weiss Asset Management and Oasis and others.
Backed by Premier Partners and Partners Investment and others.
Backed by PharmaResearch and ES Investor and others.
Backed by Metabiomed and BNH INVESTMENT and others.
Backed by SL Investment and Scale Up Partners and others.
Backed by Smile Gate Investment and InterVest and others.
Backed by DS and QUAD and others.
Backed by IMM Investment and KDB Investment and others.
Backed by Praxis Capital and DS and others.
Backed by Daily Partners and IMM Investment and others.
Backed by SKS Private Equity and Daishin Securities and others.
Backed by DSC Investment and WOORI Venture Partners and others.
Participating investors were not recorded in this snapshot.
Backed by STIC Ventures and Atinum Investment and others.
Backed by Daily Partners and Smile Gate Investment and others.
No reviewed exact national-ID connector maps South Korea company identities to the configured global filings table.; No reviewed exact national-ID connector maps South Korea company identities to the configured global filings table.
How the South Korea companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
74 of these companies (5.6%) publish at least one Android app — 151 apps in all, carrying 2M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| 아이보리 (산후조리원 신생아 실시간 영상서비스)I & I | 845.4K | — | Parenting |
| Gmate® HealthcarePhilosys | 250.2K | 4.3 | Health & Fitness |
| Gmate® ONPhilosys | 142.5K | 3.9 | Health & Fitness |
| Togispacetogi | 115.4K | — | Lifestyle |
| 스마트 임상시험 지원 올리브C(올리브씨)Alllivec | 81.6K | — | Health & Fitness |
| SONON Ultrasound AppHealcerion | 64.9K | 3.1 | Medical |
| S-Patch ExWellysis | 50.5K | — | Medical |
| ACCUNIQ ConnectACCUNIQ | 43.3K | — | Health & Fitness |
| SONON X Ultrasound AppHealcerion | 42.4K | — | Medical |
| Glucofit - AI Health CoachGlucoFit | 41.4K | — | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Wearable Technology | 44 | 1.4M | 아이보리 (산후조리원 신생아 실시간 영상서비스) 845.4K | |
| Disease Self Management | 42 | 1.4M | Gmate® Healthcare 250.2K | |
| Pediatrics | 7 | 857.5K | AKOiHeart 6.2K | |
| Online Mom & Baby Care | 3 | 848.6K | Motif AURA 2.5K | |
| Diabetes | 19 | 509.1K | Gmate® ON 142.5K | |
| Life Sciences Tech | 12 | 148.3K | 스마트 임상시험 지원 올리브C(올리브씨) 81.6K | |
| Healthcare It | 19 | 132.9K | S-Patch Ex 50.5K | |
| Imaging Diagnostics | 8 | 119.1K | SONON Ultrasound App 64.9K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 104 of 151 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
6 companies hiring · $5.21B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Galux Closes $29M in Series B Funding for AI-Driven Protein Drug Design
1ST Biotherapeutics closes oversubscribed $21.8M Series D led by Smilegate Investment.
Shaperon, a Tokyo-based company providing a compliance AI platform for regulated industries, has raised ¥730 million in Series B funding, bringing its total funding to ¥1.23 billion.
Hanwha General Insurance and Hanwha Life Insurance will participate in CHA Biotech’s third-party rights issuing, purchasing new shares of the biopharmaceutical firm worth 70 billion won and 30 billion won, respectively.
LabInCube Secures Strategic Investment from MetaBioMed to Expand MOF Technology into Medical Materials
South Korean e-Clinical tech firm CRScube acquired US counterpart Mednet to expand its presence in the North American clinical trials market.
BasgenBio also said it was selected for the government’s DIPS 1000+ initiative, which offers up to 1.1 billion won over three years through commercialization and R&D support, and that it has closed a 3.0 billion won financing with CKC Venture Capital, Pathfinder H and HLB bioStep participating.
today announced that it secured 145 billion KRW (approximately US$100 million) in convertible preferred stock investments.
Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a pact with ABL Bio.
Lilly’s recent deals, which includes a $1.3bn acquisition of RNA-based gene therapy developer Rznomics in May 2025.
Top 10 categories among 293 recorded events in the 24-month window.
7 companies with recorded IPO activity
IPO1 reports
IPO · Kosdaq2 reports
IPO1 reports
IPO1 reports
Follow-on Offering · NASDAQ6 reports
IPO · South Korea’s Kosdaq board2 reports
IPO · Kosdaq3 reports
10 tracked people moves
Appointment executive chair and CEO
Appointment Chief Growth Officer
Departure Previously Chief Executive Officer
Appointment Chairman overseeing HLB Group’s bio businesses
Resignation Previously Chief Executive Officer
Appointment Independent Board Member
Appointment Global Chief Executive Officer and President
24 recorded customer wins
Customer: sandozBiopharmaceuticals
Customer: ProturkBiopharmaceutical
Customer: regeneronPharmaceutical
Customer: Danantara Indonesia
Customer: government
Customer: Ecuadorian Electric Corporation (CELECTR)
13 recorded events
approved for saleU.K.\'s Medicines and Healthcare products Regulatory Agency
clears the way for commercial launches
ban lifted, sales resumedKorean court
approved in EuropeEuropean Medicines Agency (EMA)
9 tracked suits
Civil · Settled
RICO litigation over failed Quevedo III and Salitral power generation projectsCivil · Filed
Reported company results in the recorded window.
Median across 37 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| eli lilly→Rznomics ↗ | 2026-01-08 | $1.3B | |
| angelini pharma→SK biopharmaceuticals ↗ | Announced | 2026-01-01 | Not stated in snapshot |
| CRScube→mednet | 2025-12-22 | Not stated in snapshot | |
| eli lilly→ABL Bio ↗ | Announced | 2025-11-21 | $2.6B |
| Parataxsis Holdings→Bridge Biotherapeutics ↗ | Announced | 2025-07-28 | Not stated in snapshot |
| SillaJen→Woosung Pharmaceutical | Completed | 2025-07-02 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
0 postings in the preceding 12 months. The full 1-posting snapshot covers 1 employers.
0 tracked postings mention remote work.
1 postings specify a level.
| Company | Open roles |
|---|---|
| Astrion ↗ | 10 |
| AMT Engineering ↗ | 7 |
| Ownist ↗ | 2 |
| NGeneBio ↗ | 1 |
| G + FLAS Life Sciences ↗ | 1 |
| AbTis ↗ | 1 |
| Orum Therapeutics ↗ | 1 |
| IMB Dx ↗ | 1 |
| Company | Employees |
|---|---|
| Osstem Implant ↗ | 2,291 |
| Dong-A ST ↗ | 1,653 |
| Clinical ↗ | 741 |
| Kolmar BNH ↗ | 512 |
| Kolon Life Science ↗ | 451 |
| Boryung ↗ | 242 |
| JEISYS Medical ↗ | 197 |
| hlb group ↗ | 191 |
781 founders and chief executives across 674 companies.
Ridgeline Therapeutics, ex- I-Mab Biopharma, Viron Therapeutics, MedExact, Novartis. University of Toronto - University of Trinity College HBSc…
Founder & CEO D&D Pharmatech, Neuraly, Theraly Fibrosis, Valted Seq. Gwangju Institute of Science and Technology PhD 2006
Yonsei University, ex-Sanofi, ex-Lg Life Sciences, University of California, Berkeley
ex-CHA Biotech, LG Life Sciences, Hanwha Chemical. Yonsei University BS 1997 & MS 2000
Standigm, ex-Samsung Electronics, ex-University Of Pittsburgh School Of Medicine, Seoul National University, 2004
Abl Bio, ex-Hanwha Biologics, ex-Pharmabcine, Stanford University School of Medicine, 2000
Illimis Therapeutics, ex-Deargen, ex-Neuramedy, 한국과학기술원 / KAIST, 2013
Rokit Healthcare, ex-Celltrion Healthcare, ex-Tyco, 고려대학교, 1979
Ex- Logos Biosystem, Solborn Investment, Medy Tox. Seoul National University M.Sc 1997, Korea Advanced Institute of Science and Technology MBA 2002
ex-Asan Medical Center. Hanyang University MBA 2006
Ex- Korean Society of Gene and Cell Therapy, National Research Foundation of Korea. Cornell University PhD
ex-CJ CheilJedang. Korea University PhD 2006
51 profiles with education records.
2 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
84,512 articles in the measured 12-month window.
Life Sciences coverage across South Korea · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 10,788 |
| 2021Q3 | 12,700 |
| 2021Q4 | 10,346 |
| 2022Q1 | 13,111 |
| 2022Q2 | 12,630 |
| 2022Q3 | 13,005 |
| 2022Q4 | 20,888 |
| 2023Q1 | 16,997 |
| 2023Q2 | 16,504 |
| 2023Q3 | 21,034 |
| 2023Q4 | 14,814 |
| 2024Q1 | 16,969 |
| 2024Q2 | 15,405 |
| 2024Q3 | 16,514 |
| 2024Q4 | 22,252 |
| 2025Q1 | 23,508 |
| 2025Q2 | 17,475 |
| 2025Q3 | 22,280 |
| 2025Q4 | 20,783 |
| 2026Q1 | 22,518 |
Article volume measures coverage, not market sales.
317 recorded company events across 62 companies; percentages use that event total.
Life Sciences coverage across South Korea · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Life Sciences coverage across South Korea
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| bilateral trade | 738 | 502 | 47% |
| trade facilitation commitments | 361 | 253 | 43% |
| summit diplomacy | 271 | 156 | 74% |
| stablecoin fx impact | 251 | 36 | 597% |
| oil price volatility | 242 | 43 | 463% |
| bilateral trade terms | 241 | 170 | 42% |
| study overseas | 239 | 105 | 128% |
| overseas study | 208 | 104 | 100% |
| trade finance | 208 | 138 | 51% |
| world cup | 188 | 53 | 255% |
| aircraft wreckage | 44 | 374 | -88% |
| aircraft emergency procedures | 31 | 308 | -90% |
| flight safety measures | 40 | 284 | -86% |
| olympic team selections | 160 | 274 | -42% |
| korean dmz clashes | 102 | 226 | -55% |
Life Sciences coverage across South Korea
tariff negotiations, cuban missile crisis, free trade deals
51.4% critical · 32.0% positivequarterfinals, world cup, pre-ipo valuation
43.9% critical · 43.8% positivegdp growth rate, gdp acceleration, economic output growth
32.2% critical · 47.7% positiveLife Sciences coverage across South Korea. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Challenges in using microbes and plant systems for renewable energy and biorefinery applications.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 58.8 |
| 2023 | 55.7 |
| 2024 | 61.8 |
| 2025 | 73.9 |
Common problems researchers identify · 0216.8% of this theme group
Issues surrounding microbial hazards, nutritional quality, and health impacts of modern food processing.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 67.5 |
| 2023 | 70.6 |
| 2024 | 78.0 |
| 2025 | 100.7 |
Common problems researchers identify · 0315.8% of this theme group
Barriers in mRNA, gene regulation, and cell‑culture technologies for therapeutic and veterinary development.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2506.1 |
| 2023 | 2494.1 |
| 2024 | 2207.2 |
| 2025 | 1702.2 |
Common problems researchers identify · 0415.4% of this theme group
Problems in fertilisation, nutrient uptake, and breeding strategies to sustain global food supplies.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1622.2 |
| 2023 | 1660.9 |
| 2024 | 1789.9 |
| 2025 | 2003.4 |
Common problems researchers identify · 0515.3% of this theme group
Complexities of host‑pathogen interactions and integrated approaches to control fungal and insect threats.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 28.9 |
| 2023 | 28.2 |
| 2024 | 29.9 |
| 2025 | 36.7 |
Common problems researchers identify · 069.9% of this theme group
Widespread resistance issues linking human, animal, and environmental antimicrobial use.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 883.5 |
| 2023 | 838.1 |
| 2024 | 927.5 |
| 2025 | 957.0 |
Common problems researchers identify · 079.4% of this theme group
Diverse interdisciplinary studies lacking a clear thematic focus.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 19.1 |
| 2023 | 20.7 |
| 2024 | 17.4 |
| 2025 | 13.0 |
Cautions · 0121.5% of this theme group
Caution about in‑vitro and in‑vivo models revealing stress responses to contaminants.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1020.6 |
| 2023 | 1098.3 |
| 2024 | 921.1 |
| 2025 | 808.5 |
Cautions · 0214.6% of this theme group
Need for careful implementation of genomic tools to improve crop traits.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1418.9 |
| 2023 | 1466.0 |
| 2024 | 1622.2 |
| 2025 | 1795.1 |
Cautions · 0313.9% of this theme group
Risks and benefits of novel feed compounds for livestock performance and welfare.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 20.7 |
| 2023 | 20.7 |
| 2024 | 21.0 |
| 2025 | 16.8 |
Cautions · 0413.6% of this theme group
Evaluations of emerging food additives and contaminants with attention to consumer health.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 89.3 |
| 2023 | 91.2 |
| 2024 | 92.6 |
| 2025 | 107.8 |
Cautions · 0513.5% of this theme group
Potential pitfalls in interpreting gene‑expression and repair pathways in disease contexts.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2411.6 |
| 2023 | 2415.2 |
| 2024 | 2132.9 |
| 2025 | 1619.1 |
Cautions · 0611.7% of this theme group
Concerns about combined resistance drivers from antibiotics, biocides, and metals.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 883.5 |
| 2023 | 838.1 |
| 2024 | 927.5 |
| 2025 | 957.0 |
Cautions · 0711.3% of this theme group
Challenges in designing dose strategies to mitigate evolving pest resistance.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 64.7 |
| 2023 | 66.5 |
| 2024 | 68.3 |
| 2025 | 77.7 |
Opportunities · 0117.4% of this theme group
Promising uses of fluorescent antibodies and flow cytometry for in‑vivo diagnostics.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 564.5 |
| 2023 | 617.0 |
| 2024 | 464.1 |
| 2025 | 439.5 |
Opportunities · 0217.2% of this theme group
Opportunities in targeting gene expression to control apoptosis and tumor growth.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 367.5 |
| 2023 | 393.9 |
| 2024 | 260.7 |
| 2025 | 257.2 |
Opportunities · 0314.6% of this theme group
Development of health‑promoting ingredients and antioxidants from plant sources.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.2 |
| 2023 | 25.6 |
| 2024 | 26.8 |
| 2025 | 47.0 |
Opportunities · 0413.7% of this theme group
Innovations in DNA methylation profiling and RNA detection for disease monitoring.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2393.3 |
| 2023 | 2373.6 |
| 2024 | 2124.4 |
| 2025 | 1618.0 |
Opportunities · 0513.5% of this theme group
Exploration of plant‑derived compounds and postbiotic products to combat resistance.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 517.1 |
| 2023 | 515.5 |
| 2024 | 565.6 |
| 2025 | 643.0 |
Opportunities · 0611.9% of this theme group
Leveraging germplasm and quantitative trait loci for yield and quality enhancements.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 54.3 |
| 2023 | 44.7 |
| 2024 | 42.2 |
| 2025 | 35.0 |
Opportunities · 0711.6% of this theme group
Integrating microbial fermentation and agri‑food by‑products for circular bioeconomy solutions.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1496.6 |
| 2023 | 1561.9 |
| 2024 | 1726.8 |
| 2025 | 1958.0 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.7% |
| Promising | 30.4% | 36.9% |
| Breakthrough | 14.1% | 25.9% |
| Problem-identifying | 8.3% | 10.1% |
| Cautionary | 3.5% | 4.6% |
| Comparative | 2.4% | 3.8% |
| Critical | 1.0% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Company counts, hiring and disclosed funding across the recorded hubs.
58.7% across the displayed hubs
4 companies hiring · $3.5B disclosed funding
Explore companies in Seoul ↗
15.1% across the displayed hubs
1 companies hiring · $846.9M disclosed funding
Explore companies in Seongnam-Si ↗
7.2% across the displayed hubs
1 companies hiring · $275.5M disclosed funding
Explore companies in Daejeon ↗
6.8% across the displayed hubs
1 companies hiring · $192.0M disclosed funding
Explore companies in Suwon-Si ↗
3.8% across the displayed hubs
0 companies hiring · $80.0M disclosed funding
Explore companies in Incheon ↗3.0% across the displayed hubs
0 companies hiring · $167.3M disclosed funding
Explore companies in Yuseong District ↗
2.7% across the displayed hubs
0 companies hiring · $42.5M disclosed funding
Explore companies in Daegu ↗
2.7% across the displayed hubs
0 companies hiring · $27.5M disclosed funding
Explore companies in Busan ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 30 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗